Veru (NASDAQ:VERU) Rating Increased to Hold at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Veru (NASDAQ:VERU – Free Report) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

VERU has been the topic of several other reports. Weiss Ratings cut Veru from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Canaccord Genuity Group reissued a “buy” rating and set a $25.00 price target on shares of Veru in a research note on Thursday, June 4th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Veru currently has a consensus rating of “Hold” and an average price target of $24.50.

Read Our Latest Research Report on Veru

Veru Stock Performance

VERU opened at $2.41 on Friday. The stock has a market capitalization of $41.09 million, a price-to-earnings ratio of -3.49 and a beta of -1.17. The company has a fifty day moving average of $2.49 and a 200 day moving average of $2.52. Veru has a fifty-two week low of $2.05 and a fifty-two week high of $7.33.

Veru (NASDAQ:VERU – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, equities research analysts forecast that Veru will post -1.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in Veru in the 2nd quarter worth about $328,000. Renaissance Technologies LLC purchased a new position in shares of Veru during the first quarter valued at approximately $153,000. Finally, Royal Bank of Canada boosted its position in shares of Veru by 69.3% during the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock valued at $27,000 after buying an additional 5,008 shares during the period. 47.16% of the stock is owned by hedge funds and other institutional investors.

Veru Company Profile

(Get Free Report)

Veru Inc is a biopharmaceutical company focused on developing medicines for obesity, metabolic disorders and cancer. Its development programs are designed to address weight management, preservation of muscle mass during weight loss and treatment of certain hormone-sensitive cancers.

The company’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being evaluated for its potential to promote or preserve lean muscle while supporting weight loss. Veru has also developed oncology candidates, including sabizabulin, an oral microtubule disruptor studied in cancer indications, and other hormone-directed therapies.

Veru was formerly known as The Female Health Company and historically developed and commercialized the FC2 Female Condom, a female-controlled barrier contraceptive and sexually transmitted infection prevention product distributed in the United States and international markets.

Featured Articles